Navigation Links
Frova Phase III Study Data Demonstrates That Short-Term Prevention,Treatment Reduces Frequency and Severity of Menstrual Migraine

ly), photophobia, and phonophobia (p < 0.008; BID and QD vs. placebo), and patients experienced significantly less functional impairment during treatment with FROVA (p < 0.0001; QD and BID vs. placebo).

Both FROVA regimens were equally well tolerated with a low rate of adverse events. The most commonly reported adverse events were upper respiratory tract infection (37 patients), nausea (36 patients), and dizziness (31 patients). Most adverse events were rated mild or moderate in severity and did not increase in severity with increasing doses of FROVA; the percentage rated severe was 19 percent in the placebo group and 22 percent (once daily) and 14 percent (twice daily) in the FROVA groups.

Endo has submitted a supplemental New Drug Application (sNDA) for FROVA 2.5 mg tablets for the short-term (six days per month) prevention of MM to the U.S. Food and Drug Administration (FDA).

About Menstrual Migraine

Menstrual migraine, distinct from other types of migraines, is largely an under-recognized condition. Of the approximately 21 million women in the U.S. who experience migraines, up to 60 percent suffer from MM and its debilitating effects. More than half of these women, however, may not be correctly diagnosed, and therefore may not be receiving adequate treatment. MM has been reported to be more severe and last longer than other migraines, and women who suffer from MM may experience significant restrictions in their daily activities. For many women with MM, currently available treatment options may not adequately reduce the debilitating symptoms, such as pain, nausea and vomiting, nor the migraine's duration. For more information about MM, visit www.menstrualmigraine.org.

Important Information about FROVA

FROVA is indicated for the acute treatment of migraine attacks with or without aura in adults. FROVA is not intended for the prophylactic therapy of migraine o
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:10/22/2014)... SHANGHAI , Oct. 22, 2014 ... ) and WuXi PharmaTech (Cayman) Inc. (NYSE: ... Medicine,s comprehensive genomic profiling to biopharmaceutical companies conducting clinical ... Under the terms of the collaboration, Foundation Medicine ... component of Foundation Medicine,s FoundationOne® assay at the WuXi ...
(Date:10/20/2014)... octubre de 2014  PneumRx, Inc. ( www.pneumrx.com ... pulmonología intervencional, anunció hoy la conclusión de la ... antes de lo programado. El Estudio Clínico RENEW es ... investigación (IDE) aprobada por la FDA (Administración de ... de reducción de volumen pulmonar PneumRx RePneu, un ...
(Date:10/20/2014)... Colo. , Oct. 20, 2014  Luoxis ... (NYSE MKT: AMPE), today announced that its academic ... clinical and research potential for its novel RedoxSYS ... potential (ORP) in the body in response to ... value of ORP as a clinical marker will ...
Breaking Medicine Technology:Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 2Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 3Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 4Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 5PneumRx concluye inscripción en prueba fundamental RENEW 2PneumRx concluye inscripción en prueba fundamental RENEW 3Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 2Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 3Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 4Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 5
... Feb. 28, 2012 eCardio Diagnostics ( www.ecardio.com ... monitoring, today announced the acceptance for publication of ... Telemetry to Improve Diagnostic Accuracy and Enable More ... Arrhythmia Section of US Cardiology journal,s ...
... N.M., Feb. 28, 2012   New Mexico Software, Inc. , ... NMXC ), a developer of medical IT solutions ... healthcare community, announced today that the company,s long standing suit ... with judgment in favor of New Mexico Software. ...
Cached Medicine Technology:eCardio Announces Publication of Manuscript on The Use of Mobile Cardiac Telemetry to Improve Diagnostic Accuracy and Enable More Efficient Patient Care 2eCardio Announces Publication of Manuscript on The Use of Mobile Cardiac Telemetry to Improve Diagnostic Accuracy and Enable More Efficient Patient Care 3New Mexico Software Prevails in Lawsuit 2
(Date:10/22/2014)... On October 22, CBS will air an ... both fictional and real. The Charles E Holman ... to advocacy and philanthropy in the battle against Morgellons ... to impart truth and clarity about this misunderstood and ... misconceptions about Morgellons Disease (MD) and most ...
(Date:10/22/2014)... News) -- The United States is now mandating ... of West Africa land at one of five ... the virus. In a statement released Tuesday, ... percent of air passengers from Guinea, Liberia and ... five airports -- New York City,s Kennedy International ...
(Date:10/22/2014)... 2014 During the Western United States’ ... runs dangerously low, Southern Oregon’s water is proving resistant ... the lowest mountain snow pack on record in 2014, ... early autumn.* That was the observation of journalist-hikers Art ... “Hiking Southern Oregon,” during an interview with water advocate ...
(Date:10/22/2014)... 22, 2014 Lintelus, Inc., an event ... President of Sales, will be speaking on the subject ... Expo on October 28, at the Holiday Inn in ... booth as well as a Tech Demo at 12:45pm, ... create a more engaging event experience. , The Annual ...
(Date:10/22/2014)... 21, 2014 (HealthDay News) -- Two sisters in high ... damage. Ilina and Medha Krishen use electronic stethoscopes, ... of trouble in breathing patterns or heartbeats. Ilina, ... Michigan, wanted to find a way to detect early ... Using an electronic stethoscope, Ilina recorded one breath cycle ...
Breaking Medicine News(10 mins):Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 2Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 3Health News:Passengers From Ebola-Affected Countries Must Land at Designated U.S. Airports 2Health News:Passengers From Ebola-Affected Countries Must Land at Designated U.S. Airports 3Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 2Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 3Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 4Health News:Jay Cormier, Sr. Vice President of Sales for Lintelus, Speaks about Event Technology Integration at Meetings Technology Expo in NYC 2Health News:Teen Sisters Develop Ways to Measure Lung, Heart Damage 2
... Feb. 17 CryoLife, Inc. (NYSE: CRY ... today,that the U.S. Food and Drug Administration (FDA) has ... heart valve. The new labeling claim,relates to reducing ... the,CryoValve SG. , CryoValve SG ...
... Will ensure at least 99.99 percent uptime ... 17 Stratus Technologies, Inc. announced that ... interactive patient communication systems, has adopted the ... as a technology foundation for its flagship ...
... Event Marks 20th Anniversary of the HBA,s Prestigious Industry ... Businesswomen,s Association (HBA) today announced that its 2009 "Woman ... Chief Executive Officer of Millennium: The Takeda Oncology Company."I ... and medicine to transform cancer from a dreaded killer ...
... decisions, study says , , MONDAY, Feb. 16 (HealthDay News) -- ... they prescribe cancer medications for uses beyond what the drugs ... According to the report, published in the Feb. 17 ... online and hard-copy resource used by oncologists and pharmacists, known ...
... Feb. 17 RediClinic announced today that it has,received ... (CCA) Quality and Safety Standards by the Jefferson School ... Board of Directors adopted 10 Quality and Safety Standards ... and accrediting,organizations, as well as its Clinical Advisory Board. ...
... Perry,s Donation to Fund Renovation of Crisis ShelterATLANTA, ... Covenant House Georgia announced today that writer/director/producer Tyler ... 15-passenger van to the Atlanta-based homeless shelter. ... the complete renovation of its Crisis Shelter for ...
Cached Medicine News:Health News:FDA Clears New Immune Response Claim for the CryoValve(R) SG Pulmonary Human Heart Valve 2Health News:FDA Clears New Immune Response Claim for the CryoValve(R) SG Pulmonary Human Heart Valve 3Health News:Stratus Technologies Signs Allen Technologies as Newest Channel Partner for High Availability Avance Software 2Health News:Stratus Technologies Signs Allen Technologies as Newest Channel Partner for High Availability Avance Software 3Health News:Healthcare Businesswomen's Association Announces 2009 Woman of the Year, Dr. Deborah Dunsire, President and CEO of Millennium: The Takeda Oncology Company 2Health News:Healthcare Businesswomen's Association Announces 2009 Woman of the Year, Dr. Deborah Dunsire, President and CEO of Millennium: The Takeda Oncology Company 3Health News:Healthcare Businesswomen's Association Announces 2009 Woman of the Year, Dr. Deborah Dunsire, President and CEO of Millennium: The Takeda Oncology Company 4Health News:Doctors' Guide to Cancer Drugs May Need Revising 2Health News:RediClinic Meets Strict Quality and Safety Standards for Retail Clinics 2Health News:RediClinic Meets Strict Quality and Safety Standards for Retail Clinics 3Health News:RediClinic Meets Strict Quality and Safety Standards for Retail Clinics 4Health News:Tyler Perry Donates $110K to Covenant House Keeping Atlanta Teens off the Street 2
... to its design, this is the ... stone therapy in urinary and biliary ... a multipurpose lithotripter with other applications ... nephrolithotomy. ,The basic system comprises the ...
All the power and performance of the STS - T but now available with a stand-alone 9" II C-Arm...
... The Compact Sigma is designed to ... Quick, precise mechanical coupling eliminates clumsy ... be performed as well. Dorniers patented ... too. ,Positioning is simple using the ...
The latex free, hydrophilic Self-Cath Plus is designed for single use, intermittent self-catheterization. The unique hydrophilic coating activates immediately upon exposure to water for fast, clean...
Medicine Products: